Yüklüyor......
Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
Previous studies have established the rationale for NK105, a nanomicellar formulation of paclitaxel, administered every 3 weeks. The aim of this phase I study was to determine the recommended dose and pharmacokinetics of weekly administered NK105. NK105 was administered by a 30-min infusion once wee...
Kaydedildi:
| Yayımlandı: | Invest New Drugs |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer US
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5099351/ https://ncbi.nlm.nih.gov/pubmed/27595901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0381-4 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|